Multiple studies have shown the overexpression of intestinal TNF-α in patients with CD (Braegger et al., 1992; Murch et al., 1993; Reibetanz and Germer, 2015; Paredes et al., 2019), and anti-TNF-α antibody therapy has been widely used to treat the patients with IBD (Ricart et al., 2000; Reibetanz and Germer, 2015). The gene discussed is TNF; the disease is inflammatory bowel disease.